|Bid||79.79 x 1200|
|Ask||80.00 x 800|
|Day's range||76.66 - 80.08|
|52-week range||68.44 - 91.40|
|Beta (5Y monthly)||0.49|
|PE ratio (TTM)||27.82|
|Earnings date||02 Feb 2022 - 07 Feb 2022|
|Forward dividend & yield||2.76 (3.59%)|
|Ex-dividend date||14 Dec 2021|
|1y target est||92.31|
Gilead (GILD) gets FDA approval for label expansion of Veklury for the treatment of non-hospitalized patients at high risk for COVID-19 disease progression.
KENILWORTH, N.J., January 24, 2022--Merck Provides U.S. and Japan Regulatory Update for Gefapixant
Dr. Owais Durrani, Emergency Medicine Physician, joins Yahoo Finance Live to discuss including the booster shot in definitions of being fully vaccinated, monitoring and testing for potential COVID symptoms, transmissibility in hospitals for non-COVID patients, and the outlook on variant case numbers.